OgilvyHealthPR won the account following a competitive pitch and replaces Chandler Chicco Companies' medical education division Litmus. Pradaxa is an oral anticoagulant, used to prevent and treat acute and chronic thromboembolic disease.
OgilvyHealthPR will work with sister company Ogilvy Healthworld Digital to develop and implement an integrated comms programme. Ogilvy Healthworld Digital is headed up by managing partners Caroline Howe and David Davenport-Firth.
Pradaxa is currently used in more than 50 countries for primary prevention of venous thromboembolic occurrences in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. It is also being investigated for the prevention of stroke in patients with atrial fibrillation (abnormal heart rhythm).
The account will be led by OgilvyHealthPR business unit head Deanne Wallace, who is based in London.
OgilvyHealthPR already works on other global accounts with Boehringer Ingelheim, including its diabetes portfolio.
Additionally, the agency has bolstered its senior team with the appointment of Ben Fisher as associate director. Fisher has ten years' experience in healthcare comms and joins the agency from Porter Novelli where he was an account director.
He will head up the Boehringer Ingelheim diabetes portfolio, in addition to focusing on new business.